Literature DB >> 620410

Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.

I Jardine, C Fenselau, M Appler, M N Kan, R B Brundrett, M Colvin.   

Abstract

Unambiguous and sensitive methods based on gas chromatography-chemical ionization mass spectrometry have been developed to quantitate cyclophosphamide and two alkylating and cytotoxic metabolites, phosphoramide mustard and nornitrogen mustard. The levels of these materials have been determined in the plasma and urine of five patients receiving cyclophosphamide, 60 or 75 mg/kg i.v. Peak plasma levels of phosphoramide mustard of 50 to 100 nmoles/ml were found at 3 hr after cyclophosphamide administration. Variable levels of nornitrogen mustard were found in the plasma. This product may be arising in part from the decomposition of other metabolites during sample storage and preparation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 620410

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Intravenous infusions of ifosfamide/mesna and perturbation of warfarin anticoagulant control.

Authors:  G Hall; M J Lind; M Huang; A Moore; A Gane; J T Roberts; B M Cantwell
Journal:  Postgrad Med J       Date:  1990-10       Impact factor: 2.401

2.  Microcarrier-attached rat hepatocytes as a xenobiotic-metabolizing system in cocultures.

Authors:  J U Voss; H Seibert
Journal:  Cell Biol Toxicol       Date:  1991-10       Impact factor: 6.691

3.  Phosphoramide mustard exposure induces DNA adduct formation and the DNA damage repair response in rat ovarian granulosa cells.

Authors:  Shanthi Ganesan; Aileen F Keating
Journal:  Toxicol Appl Pharmacol       Date:  2014-12-09       Impact factor: 4.219

4.  Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites.

Authors:  F D Juma; H J Rogers; J R Trounce
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

5.  Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokinetic study.

Authors:  R N Harris; P J Basseches; P L Appel; A M Durski; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  Occupational exposure to cytotoxic drugs in two UK oncology wards.

Authors:  E Ziegler; Howard J Mason; P J Baxter
Journal:  Occup Environ Med       Date:  2002-09       Impact factor: 4.402

7.  Preclinical pharmacokinetics and stability of isophosphoramide mustard.

Authors:  J J Zheng; K K Chan; F Muggia
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  Application of a microsomal drug activation system in a human tumor cloning assay.

Authors:  H R Metelmann; D D Von Hoff
Journal:  Invest New Drugs       Date:  1983       Impact factor: 3.850

Review 9.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

10.  Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma.

Authors:  P M Wilkinson; P A O'Neill; N Thatcher; S B Lucas
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.